Business Wire
18 Nov 2026, 07:30 UTC · 1h ago
Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
Impact · against what's priced in
Innate Pharma is presenting early-stage clinical data for IPH4502, marking a standard developmental milestone. While positive, the initial nature of Phase 1 data typically provides a modest catalyst rather than a fundamental re-rating.
- INPX+0.20
No priced-in read yet
- In context
The presentation of initial Phase 1 clinical data for IPH4502 provides a positive update on the candidate's development progress.
Read from the article alone

Search tags




